We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novartis' Ianalumab Wins Breakthrough Therapy Tag for Sjogren's Disease
Read MoreHide Full Article
Key Takeaways
Novartis' ianalumab won FDA Breakthrough Therapy tag for Sjogren's disease after meeting phase III endpoints.
Per NVS, phase III NEPTUNUS studies showed significant ESSDAI reductions vs. placebo.
Novartis plans global regulatory filings from early 2026 for ianalumab.
Novartis (NVS - Free Report) announced that the FDA granted Breakthrough Therapy designation to its pipeline candidate, ianalumab for the treatment of adult patients with Sjogren’s disease — a chronic, systemic autoimmune disorder.
Ianalumab is an investigational monoclonal antibody with a novel dual mechanism of action, designed to deplete B-cells by targeting the BAFF receptor while inhibiting B-cell activation and survival.
The Breakthrough Therapy designation for ianalumab is supported by data from the phase III NEPTUNUS-1 and NEPTUNUS-2 studies. These global, multicenter, pivotal studies achieved their primary endpoints by demonstrating clinically meaningful and statistically significant improvements in disease activity as measured by a reduction in ESSDAI compared with placebo. The ESSDAI score is a popular clinical tool used to measure systemic disease activity in patients with primary Sjogren's syndrome.
Ianalumab was well-tolerated and showed a favorable safety profile despite certain side effects.
Novartis intends to submit regulatory applications to several global health authorities (including the FDA) to commercialize ianalumab beginning in early 2026. Ianalumab would become the first targeted therapy for patients with Sjogren’s disease, if approved.
Over the past year, NVS shares have rallied 48% compared with the industry’s 24.1% rise.
Image Source: Zacks Investment Research
Ianalumab was added to Novartis’ pipeline following collaboration with MorphoSys AG, which was acquired by the company in 2024.
The FDA also granted the Fast Track designation to ianalumab in 2016.
Sjogren’s disease is a progressive, heterogeneous, rheumatic, autoimmune disorder that causes inflammation and tissue damage across multiple organs, along with symptoms like dryness, fatigue, and pain, and can significantly reduce quality of life. The disease carries an increased risk of lymphoma. Currently, there are no approved disease-modifying therapies for this condition.
More on Novartis’ Ianalumab
Besides Sjogren’s disease, ianalumab is being studied in several other B-cell-driven autoimmune diseases, including immune thrombocytopenia (ITP), systemic lupus erythematosus, lupus nephritis, warm autoimmune hemolytic anemia, and diffuse cutaneous systemic sclerosis. The candidate showed promising efficacy and a favorable safety profile in systemic lupus erythematosus and immune thrombocytopenia studies.
In December 2025, Novartis announced positive results from the phase III VAYHIT2 study evaluating ianalumab plus eltrombopag in patients with ITP previously treated with corticosteroids.
Ianalumab (9 mg/kg) plus eltrombopag extended ITP disease control by 45%, based on the primary endpoint of time to treatment failure, which assesses how long patients maintain safe platelet levels during and after the treatment period.
Notably, 62% of patients treated with ianalumab in combination with eltrombopag achieved sustained platelet response in six months compared with 39% with placebo plus eltrombopag.
Novartis plans to submit the VAYHIT2 data from second-line ITP, with results from the ongoing first-line ITP trial, VAYHIT1, to health authorities in 2027.
Over the past 60 days, estimates for MannKind’s 2026 earnings per share have increased from 7 cents to 9 cents. MNKD shares have declined 13.3% over the past year.
MannKind’s earnings beat estimates in two quarters, missed in one and were in line in the remaining quarter, the average surprise being 33.33%.
Over the past 60 days, 2026 loss per share estimates for Keros Therapeutics have narrowed from $3.56 to $3.36. KROS shares have surged 73.6% over the past year.
Keros Therapeutics’ earnings beat estimates in three of the trailing four quarters and missed in the remaining quarter, the average surprise being 9098.63%.
Over the past 60 days, estimates for Amicus Therapeutics’ 2026 earnings per share have declined from 67 cents to 65 cents. FOLD shares have soared 52.2% over the past year.
Amicus Therapeutics’ earnings beat estimates in one quarter and missed in the remaining three trailing quarters, the negative average earnings surprise being 20.21%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Novartis' Ianalumab Wins Breakthrough Therapy Tag for Sjogren's Disease
Key Takeaways
Novartis (NVS - Free Report) announced that the FDA granted Breakthrough Therapy designation to its pipeline candidate, ianalumab for the treatment of adult patients with Sjogren’s disease — a chronic, systemic autoimmune disorder.
Ianalumab is an investigational monoclonal antibody with a novel dual mechanism of action, designed to deplete B-cells by targeting the BAFF receptor while inhibiting B-cell activation and survival.
The Breakthrough Therapy designation for ianalumab is supported by data from the phase III NEPTUNUS-1 and NEPTUNUS-2 studies. These global, multicenter, pivotal studies achieved their primary endpoints by demonstrating clinically meaningful and statistically significant improvements in disease activity as measured by a reduction in ESSDAI compared with placebo. The ESSDAI score is a popular clinical tool used to measure systemic disease activity in patients with primary Sjogren's syndrome.
Ianalumab was well-tolerated and showed a favorable safety profile despite certain side effects.
Novartis intends to submit regulatory applications to several global health authorities (including the FDA) to commercialize ianalumab beginning in early 2026. Ianalumab would become the first targeted therapy for patients with Sjogren’s disease, if approved.
Over the past year, NVS shares have rallied 48% compared with the industry’s 24.1% rise.
Image Source: Zacks Investment Research
Ianalumab was added to Novartis’ pipeline following collaboration with MorphoSys AG, which was acquired by the company in 2024.
The FDA also granted the Fast Track designation to ianalumab in 2016.
Sjogren’s disease is a progressive, heterogeneous, rheumatic, autoimmune disorder that causes inflammation and tissue damage across multiple organs, along with symptoms like dryness, fatigue, and pain, and can significantly reduce quality of life. The disease carries an increased risk of lymphoma. Currently, there are no approved disease-modifying therapies for this condition.
More on Novartis’ Ianalumab
Besides Sjogren’s disease, ianalumab is being studied in several other B-cell-driven autoimmune diseases, including immune thrombocytopenia (ITP), systemic lupus erythematosus, lupus nephritis, warm autoimmune hemolytic anemia, and diffuse cutaneous systemic sclerosis. The candidate showed promising efficacy and a favorable safety profile in systemic lupus erythematosus and immune thrombocytopenia studies.
In December 2025, Novartis announced positive results from the phase III VAYHIT2 study evaluating ianalumab plus eltrombopag in patients with ITP previously treated with corticosteroids.
Ianalumab (9 mg/kg) plus eltrombopag extended ITP disease control by 45%, based on the primary endpoint of time to treatment failure, which assesses how long patients maintain safe platelet levels during and after the treatment period.
Notably, 62% of patients treated with ianalumab in combination with eltrombopag achieved sustained platelet response in six months compared with 39% with placebo plus eltrombopag.
Novartis plans to submit the VAYHIT2 data from second-line ITP, with results from the ongoing first-line ITP trial, VAYHIT1, to health authorities in 2027.
Novartis’ Zacks Rank & Stocks to Consider
NVS currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are MannKind (MNKD - Free Report) , Keros Therapeutics (KROS - Free Report) and Amicus Therapeutics (FOLD - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for MannKind’s 2026 earnings per share have increased from 7 cents to 9 cents. MNKD shares have declined 13.3% over the past year.
MannKind’s earnings beat estimates in two quarters, missed in one and were in line in the remaining quarter, the average surprise being 33.33%.
Over the past 60 days, 2026 loss per share estimates for Keros Therapeutics have narrowed from $3.56 to $3.36. KROS shares have surged 73.6% over the past year.
Keros Therapeutics’ earnings beat estimates in three of the trailing four quarters and missed in the remaining quarter, the average surprise being 9098.63%.
Over the past 60 days, estimates for Amicus Therapeutics’ 2026 earnings per share have declined from 67 cents to 65 cents. FOLD shares have soared 52.2% over the past year.
Amicus Therapeutics’ earnings beat estimates in one quarter and missed in the remaining three trailing quarters, the negative average earnings surprise being 20.21%.